Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1524-4725.2003.29031.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RIOK1: A Novel Oncogenic Driver in Hepatocellular Carcinoma.
Cancer Med
February 2025
Centre for Medical Research, Ningbo No.2 Hospital, Ningbo, China.
Background: Hepatocellular carcinoma (HCC) is one of the most common and highly lethal cancers worldwide. RIO kinase 1 (RIOK1), a protein kinase/ATPase that plays a key role in regulating translation and ribosome assembly, is associated with a variety of malignant tumors. However, the role of RIOK1 in HCC remains largely unknown.
View Article and Find Full Text PDFElbow Ulnar Collateral Ligament Repair With Suture Tape Augmentation Versus Reconstruction Should Be Determined Using Precise Imaging and Indications.
Arthroscopy
January 2025
The Everett J. and Marian Gordon Professor of Orthopaedic Surgery and Sports Medicine The Rothman Institute, Thomas Jefferson University Philadelphia, Pennsylvania, U.S.A. Electronic address:
Current surgical treatment options for ulnar collateral ligament injury of the elbow include both reconstruction and repair. A growing amount of research has evaluated the outcomes of these various techniques in a variety of study designs. Large national database assessment indicates that overall failure rates are low and complication rates are similar between UCL reconstruction and UCL repair techniques.
View Article and Find Full Text PDFConsensus recommendations for measuring the impact of contraception on the menstrual cycle in contraceptive clinical trials.
Contraception
January 2025
MSI Reproductive Choices, London, England, United Kingdom.
Objective: We sought to develop consensus recommendations for measurement and analysis of data on contraceptive-induced menstrual changes (CIMCs) in contraceptive clinical trials. We built upon previous standardization efforts over the last 50 years and prioritized input from a variety of global experts and current regulatory authority guidance on patient-reported outcomes.
Study Design: We completed a formal consensus-building process with an interdisciplinary group of 57 experts from 30 organizations and 14 countries in five global regions who work across academia, nonprofit research organizations, the pharmaceutical industry, and funding agencies.
Future directions in the evaluation and management of newly diagnosed metastatic cancer.
Crit Rev Oncol Hematol
January 2025
Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA. Electronic address:
There is a much debate regarding optimal selection in patients with metastatic cancer who should undergo local treatment (surgery or radiation treatment) to the primary tumor and/or metastases. Additionally, the optimal treatment of newly diagnosed metastatic cancer is largely unclear. Current prognostication systems to best inform these clinical scenarios are limited, as all metastatic patients are grouped together as having Stage IV disease without further incorporation of patient and disease-specific covariates that significantly impact patient outcomes.
View Article and Find Full Text PDFNegative pressure wound therapy on a musculocutaneous free flap in no skin edge wound bed: A case report.
Int J Surg Case Rep
January 2025
Department of Plastic and Breast Surgery, Aarhus University Hospital, Denmark.
Introduction: Necrotising soft tissue infection (NSTI) is an exceptionally dangerous infectious disease targeting soft tissues with high mortality as well as morbidity. The aim of reconstructive surgery after initial debridement is to maintain function as well as to achieve a satisfactory cosmetic result.
Presentation Of Case: A 50-year-old male presented with necrotising soft tissue infection on the thorax and left upper arm following mastectomy for breast cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!